Generic drug companies stand to experience a very exciting time over the next few years, as patents for many of the top grossing brand name drugs are expiring. With patents expiring for branded drugs such as Cozaar and Hyzaar whose combined yearly sales crossed the $1 billion dollar mark last year, the opportunity for increased generic sales is up.
While the release of patented drugs is beneficial to generic makers, it can prove devastating to the companies that originally create them. When exclusive sales rights expire, branded companies generally see a large decline in revenues and profits. This has prompted some companies in the branded drug market to start investing in the generic markets themselves.
Branded companies are starting to acquire generic businesses.